Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2Phase 4 1

Status

Completed 5Unknown 3Not yet recruiting 1

Sponsor Class

OTHER 3INDUSTRY 2

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 2Breast 2Sarcoma 1

Conditions

Neoplasm Metastasis 3Multiple Myeloma 2Breast Neoplasms 2Sarcoma, Ewing 1Neoplastic Cells, Circulating 1Neoplasms, Plasma Cell 1Neoplasms 1

Interventions

Cyclophosphamide 1495Cisplatin 1431Paclitaxel 1339Radiotherapy 1308Carboplatin 1264Gemcitabine 1225Docetaxel 1134Bevacizumab 1068Fluorouracil 906Doxorubicin 799Dexamethasone 753Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 693Etoposide 674Irinotecan 639Filgrastim 624Nivolumab 585Cytarabine 585Leucovorin 582Vincristine 512Cetuximab 478Prednisone 477Bortezomib 472Trastuzumab 469Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 443Lenalidomide 434

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Completed × Diphosphonates × Clear all
NCT00987636 2019-10-22

EWING2008

University Hospital Muenster

Phase 3 Completed
907 enrolled
Sarcoma

Neoplasm Metastasis, Sarcoma, Ewing

NCT01215344 2018-05-15

First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade

Vanderbilt-Ingram Cancer Center

Phase 2 Completed
36 enrolled 8 charts
Plasma cell

Multiple Myeloma

NCT01129336 2014-05-20

MACS1295

Novartis

Phase 4 Completed
44 enrolled 10 charts
Breast

Breast Neoplasms, Neoplastic Cells, Circulating, Neoplasm Metastasis

NCT00091832 2014-01-28

Denosumab (AMG 162) in Bisphosphonate Naive Metastatic Breast Cancer

Amgen

Phase 2 Completed
255 enrolled 34 charts
Breast

Breast Neoplasms, Neoplasm Metastasis, Neoplasms

NCT00222053 2010-04-02

IFM 99-02 Thalidomide in Myeloma

University Hospital, Toulouse

Phase 3 Completed
800 enrolled
Plasma cell

Multiple Myeloma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡